The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics
Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.
 
Sandra P. D'Angelo
Consulting or Advisory Role - Adaptimmune; Amgen; EMD Serono; GlaxoSmithKline; Immune design; Immunocore; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
 
Mihaela Druta
Honoraria - Adaptimmune; Blueprint Genetics; Daiichi Sankyo; Deciphera; Epizyme
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; Apexigen; Bayer; Cytokinetics; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeuticuses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), •Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly
 
David A. Liebner
Consulting or Advisory Role - Blueprint Medicines; Epizyme; Foundation Medicine
Patents, Royalties, Other Intellectual Property - Co-holder of 2 patents ("Methods for Predicting Prognosis") that has been licensed to a private company, MatchTX, LLC.
Travel, Accommodations, Expenses - Blueprint Medicines; Epizyme; Foundation Medicine
 
Scott Schuetze
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Blueprint Medicines
 
Aisha N. Hasan
No Relationships to Disclose
 
Andrew P. Holmes
Employment - Phastar (I); Veramed
Travel, Accommodations, Expenses - Veramed
 
Anne Huff
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline; Pfizer
 
Gurpreet Singh Kapoor
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Stefan Zajic
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Bayer; Bayer; Blueprint Medicines; Deciphera; Immune Design
Research Funding - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; MedImmune